Finance

Albuferon maker reports increased net loss in 2003

Published in Gene Therapy Weekly, March 11th, 2004

Human Genome Sciences, Inc., (HGSI) announced financial results for the quarter and full year periods ended December 31, 2003, and provided guidance for financial results anticipated for the full year 2004.

The company's actual net loss for the year, in conformity with generally accepted accounting principles (GAAP), was $185.3 million, or $1.44 per share. This compares to the pro forma net loss for 2002 of $173.3 million, or $1.35 per share. The increase in the net loss is primarily due to reduced net interest income partially offset by increased revenue.

The company's actual net loss for 2003 of $185.3 million, or $1.44 per share, compares to its...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-03-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry